Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4...
Obesity
Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its subsidiary Chongqing Yaopharma...
CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...
Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance
BrightGene Bio-Medical Techonology Co., Ltd. (SHA: 688166) disclosed that China’s National Medical Products Administration (NMPA) has...
Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026
Novo Nordisk A/S (NYSE: NVO) released an internal memorandum outlining a sweeping re‑organization of its...
Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...
Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...
Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...
Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
China‑based Ascletis Pharma Inc. (HKG: 1672) announced the selection of ASC36, a once‑monthly subcutaneous injectable...
Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed...
Innovent’s Mazdutide Meets Phase III Endpoint in Type 2 Diabetes and Obesity Trial
Innovent Biologics (HKG: 1801) announced on October 27, 2025, that its fourth Phase III clinical...
Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia
Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received...
Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India
Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited (BOM: 500087, NSE: CIPLA) today announced a...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons
Eli Lilly & Co. (NYSE: LLY) announced that it has discontinued a phase I/II trial of...